A comprehensive overview of urogenital, anorectal and oropharyngeal Neisseria gonorrhoeae testing and diagnoses among different STI care providers: a cross-sectional study

Casper D. J. den Heijer 1,2*, Christian J. P. A. Hoebe 1,2, Geneviève A. F. van Liere 1,2, Jan E. A. M. van Bergen 3,4, Jochen W. L. Cals 5, Frans S. Stals 6 and Nicole H. T. M. Dukers-Muijters 1,2

Abstract

Background: Gonorrhoea, caused by Neisseria gonorrhoeae (NG), can cause reproductive morbidity, is increasingly becoming resistant to antibiotics and is frequently asymptomatic, which shows the essential role of NG test practice. In this study we wanted to compare NG diagnostic testing procedures between different STI care providers serving a defined geographic Dutch region (280,000 inhabitants).

Methods: Data on laboratory testing and diagnosis of urogenital and extragenital (i.e. anorectal and oropharyngeal) NG were retrieved from general practitioners (GPs), an STI clinic, and gynaecologists (2006–2010). Per provider, we assessed their contribution regarding the total number of tests performed and type of populations tested, the proportion of NG positives re-tested (3–12 months after treatment) and test-of-cure (TOC, within 3 months post treatment).

Results: Overall, 17,702 NG tests (48.7% STI clinic, 38.2% GPs, 13.1% gynaecologists) were performed during 15,458 patient visits. From this total number of tests, 2257 (12.7%) were extragenital, of which 99.4% were performed by the STI clinic. Men were mostly tested at the STI clinic (71%) and women by their GP (43%).

NG positivity per visit was 1.6%; GP 1.9% (n = 111), STI clinic 1.7% (n = 131) and gynaecology 0.2% (n = 5). NG positivity was associated with Chlamydia trachomatis positivity (OR: 2.06, 95% confidence interval: 1.46–2.92). Per anatomical location, the proportion of NG positives re-tested were: urogenital 20.3% (n = 36), anorectal 43.6% (n = 17) and oropharyngeal 57.1% (n = 20). NG positivity among re-tests was 16.9%.

Proportions of NG positives with TOC by anatomical location were: urogenital 10.2% (n = 18), anorectal 17.9% (n = 7) and oropharyngeal 17.1% (n = 6).

Conclusions: To achieve best practice in relation to NG testing, we recommend that: 1) GPs test at extragenital sites, especially men who have sex with men (MSM), 2) all care providers consider re-testing 3 to 12 months after NG diagnosis and 3) TOC is performed following oropharyngeal NG diagnosis in settings which provide services to higher-risk men and women (such as STI clinics).
Background

Gonorrhoea, caused by the Gram-negative diplococcus *Neisseria gonorrhoeae* (NG), is a bacterial sexually transmitted infection (STI) which causes reproductive morbidity, can facilitate human immunodeficiency virus (HIV) transmission, and is increasingly becoming resistant to antibiotics [1]. The high number of asymptomatic episodes in urogenital (in women) and extragenital (in men and in women, i.e. anorectal and oropharyngeal) syndromes in urogenital (in women) and extragenital (in men [11]) is not mentioned in the guidelines for gynaecologists [13].

Regarding extragenital NG testing, GP guidelines recommend additional anorectal NG testing in the case of anal sex and/or anal symptoms and/or MSM, and additional oropharyngeal testing for prostitutes, MSM, and everyone with oral sex and oropharyngeal symptoms. For STI clinics, oropharyngeal and anorectal testing is routinely advised for prostitutes and needs to be considered after unprotected oral and anal sex, respectively, for heterosexual women. Because of the high prevalence of extragenital NG, oropharyngeal and anorectal testing is routinely advised for MSM. With respect to guidelines for gynaecologists, oropharyngeal and/or anorectal NG testing should be performed in the case of exposure (passive anal and/or oral sex) and/or symptoms, respectively, for men as well as women.

With respect to NG test practice, Dutch STI clinic guidelines recently (2015) recommended re-testing within 4–6 months after a positive NG test, with a maximum interval of 1 year, in order to detect new infections, because of a high NG prevalence among men and women previously treated for NG [11]. Following a NG positive test, the Centers for Disease Control and Prevention (CDC) recommends re-testing after 3 months, and no later than 12 months [1]. On the other hand, Dutch GPs and gynaecologists have a re-testing policy based on risk behaviour [1, 13]. This means that a re-test should be performed when the patient is likely re-exposed to an untreated person with NG (the source). The optimal testing interval after such exposure is 3 weeks, and nucleic acid amplification tests (NAAT) are the first-choice tests followed by culture.

Increasing antimicrobial resistance has resulted in international guidelines including the recommendation that a test-of-cure (TOC) is performed 2 weeks after the completion of NG treatment (for NAAT) [5, 14]. Indeed, mathematical modelling has suggested that the most effective control strategy for the treatment of resistant NG is to follow-up infections that have already been treated in order to assess treatment failures, rather than only testing (and treating) more patients [15]. Current Dutch STI clinic, GP and gynaecologist guidelines recommend a TOC when the first-choice antibiotic (ceftriaxone) was not given and when symptoms persist or recur [11–13]. In addition, Dutch GPs should perform a TOC in pregnant women (4–6 weeks after treatment) [12] and STI clinic guidelines advise a TOC in the case of oropharyngeal NG because it is more difficult to eradicate than urogenital and anorectal NG, and is frequently asymptomatic [11].

In combination, the testing and subsequent adequate treatment of positives is an essential tool for NG control and needs to be optimised in order to reduce NG
transmission, NG-related morbidity and the chance of increasing antibiotic resistance among NG strains.

Here, we compared NG diagnostic testing practices between the different STI care providers (GPs, an STI clinic and gynaecologists) from one defined geographic Dutch region. We also assessed whether NG positives were re-tested within 3–12 months in order to detect a new infection, and if TOC (within 3 months after treatment) was applied following NG treatment. We hope that our results will help to improve NG testing protocols for different STI care providers.

Methods
Study population
Data sources used to identify all NG tests administered by the STI clinic, GPs and gynaecologists from January 2006 to August 2010 were set up in such a way that each row represented one patient visit (during which ≥1 NG test was taken). Per visit, a maximum of three NG tests could be taken, depending on the anatomical locations tested/sampled (i.e. urogenital, anorectal and oropharyngeal). Data were retrieved from our own public health STI clinic medical records (n = 28,459 tests from 21,570 patient visits) and from the Department of Medical Microbiology (Zuyderland Medical Centre) serving both GPs and gynaecologists (n = 9214 tests from 9204 patient visits). The final dataset for analyses therefore included: 17,702 tests from 15,458 patient visits: STI clinic (n = 9764 tests from 7528 patient visits), GPs (n = 5903 tests from 5902 patient visits) and gynaecologists (n = 2035 tests from 2028 patient visits) (Fig. 1).

CT tests and diagnoses were retrieved from a dataset with the same selection criteria, which resulted in a total of 31,647 CT tests from 29,366 visits [10]. All patients who were tested for NG, were tested for CT as well.
Social economic status (SES) scores were extracted per postal code area and are based on national data on income, educational level and employment (see below).

NG diagnosis
STI clinic specimens mainly comprised self-collected vaginal swabs and urine. Clinician-collected urethral and cervical swabs were predominantly used by GPs and gynaecologists. Anorectal (mainly self-collected) and oropharyngeal (provider-collected) swabs were used for testing these respective anatomical locations. Strand displacement amplification (SDA) and polymerase chain reaction (PCR) for NG testing (Becton Dickinson Probe-Tec ET system, Maryland, USA and from 6 to 1-2010 Abbott M2000, Illinois, USA) were used for the evaluation of all specimens. In our study population, no NG diagnosis was made by culture.

Statistical analyses
First, a descriptive analysis was performed to assess the contribution of each STI care provider regarding the number of patient visits and positives diagnosed. Patient visits during which NG tests were taken that turned out positive were defined as ‘test positive visits’. NG positivity refers to the proportion of test positive visits with the denominator being the total number of patient visits.

Second, to assess the factors associated with 1) the number of patient visits and 2) test positive visits, multivariable Poisson and logistic regression analyses were performed, respectively, including age (16–21, 22–24, 25–29, 30–39 and 40+), SES (low, middle and high, based on tertiles), and test calendar year (continuous). Moreover, a concurrent (i.e. at the same visit) CT test positive result was included as a factor in the analyses of the test positive visits. In the evaluation of the number of patient visits, differences between providers (GP, STI clinic and gynaecologists) were evaluated (the same comparisons could not reliably be carried out for the test positive visits due to low numbers). Denominator data for all subgroups included in Poisson regression analyses were retrieved from Statistics Netherlands (http://www.cbs.nl; age, sex and test year) and the Netherlands Institute for Social Research (http://www.scp.nl; SES) [10].

The multivariable Poisson analysis was initially performed including ‘provider’ and any potential confounders (age, test year and SES) to test for differences in outcomes between STI care providers. Subsequent analyses to determine associations between the outcomes and age, test year and SES were stratified by STI care provider, because of statistically significant interaction-terms between ‘provider’ and the other factors.

All analyses were stratified by sex, due to interactions. The outcome measures presented are adjusted for age, test year, a concurrent CT test positive result and SES (where appropriate).

Third, the proportion of NG positive patients who were re-tested was compared across providers. A re-test was defined as a NG test taken between 3 and 12 months after the NG positive test visit, in accordance with the CDC guidelines [1]. Moreover, NG positivity was assessed among the re-tests per STI care provider. In addition, patient characteristics of patients who were re-tested were compared with those who were not re-tested by means of binary logistic regression analyses.

Finally, TOC was evaluated for the different STI care providers in a similar way as described above for the re-tests. TOC was defined as a NG test taken between 2 weeks and 3 months after the NG positive test visit [14]. For both re-test and TOC only the first positive test of a patient was included in the analyses. Tests taken within 2 weeks from this first positive test (n = 7) were excluded from the TOC and re-test analyses.

Analyses were performed using SPSS version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp.). A P-value <0.05 was considered statistically significant.

Results
NG testing practices
In total, 11,459 individuals contributed to 17,702 NG tests that were performed during 15,458 patient visits. These included 15,445 urogenital, 1416 anorectal and 841 oropharyngeal tests. The number of NG tests per STI care provider were: STI clinic (n = 9764), GPs (n = 5903) and gynaecologists (n = 2035). In total, 811 anorectal tests were performed in men and 605 in women. Oropharyngeal tests were performed in 521 men and in 320 women. Extragenital tests were almost exclusively (99%, n = 2243) performed at the STI clinic.

Contribution of different STI care providers in testing
Overall, the STI clinic accounted for 49% (n = 7528) of all patient visits, whereas GPs and gynaecologists accounted for 38% (n = 5902) and 13% (n = 2028), respectively (Fig. 2a and Table 1). Men were mostly tested by the STI clinic (71% of men), while women were more often tested by their GPs (43% of women, Fig. 2b and Table 1).

After adjusting for age, test year and SES, the STI clinic performed most tests in men, whereas both the STI clinic and GPs performed more tests than the gynaecologists in women (Table 1).

NG positivity
Taking into account all 15,458 patient visits, 247 (1.6%) resulted in at least one NG positive test. Proportion of test positive visits per STI care provider were: GP 1.9%
NG positivity was: urogenital (1.2%, n = 191), anorectal (3.3%, n = 47) and oropharyngeal (4.5%, n = 38). Visits resulting in positive NG tests from more than one anatomical location were only observed at the STI clinic. In 73% (77.8% in men and 59.1% in women) of the extragenital NG infections, no urogenital NG was diagnosed concurrently.

The urogenital NG positivity in men was 2.4% (123/5177) and 0.7% (68/10,268) in women. For extragenital NG, these numbers were: 4.8% (39/811) in men and 1.3% (8/605) in women (anorectal); and 4.6% (24/521) in men and 4.4% (14/320) in women (oropharyngeal).

Contribution of different STI care providers in NG positivity
Overall, GPs accounted for 45% (n = 111), the STI clinic for 53% (n = 131), and gynaecologists for 2.0% (n = 5) of all test positive visits (Fig. 2a). Both men and women had most test positive visits at the STI clinic (55% of visits from men and 50% of visits from women, Fig. 2b).

After adjusting for STI care provider, age, test year and SES, NG positivity in men was higher at the GP than at the STI clinic, and in women NG positivity was higher at the GP and STI clinic than at the gynaecologist (Table 2). Concurrently testing CT positive was associated with NG positivity in both men and women (Table 2), and this was observed across all providers.

NG re-test
Of the 177 urogenital test positive visits, 36 (20.3%) were followed by a re-test. Stratified by STI care providers, this proportion was: GP 12.7% (13/102), STI clinic 32.9% (23/70) and gynaecology 0% (0/5). For extragenital NG (only diagnosed at the STI clinic) the proportion followed by a re-test was: 43.6% (17/39) for anorectal NG and 57.1% (20/35) for oropharyngeal NG.

Overall, re-test positivity was 16.9% (10/59), stratified by anatomical location: urogenital 13.9% (n = 5; three at the GP and two at the STI clinic), anorectal 17.6% (3/17) and oropharyngeal 10.0% (2/20).

Patients aged 40+ were re-tested more frequently than 16–21 year olds, and a higher proportion of patients with high SES were re-tested compared with low SES patients (Table 3).

Test-of-cure
A TOC was performed after 18 of 177 (10.2%) urogenital NG test positive visits. Per STI care provider, these numbers were: GP 11.8% (12/102), STI clinic 5.7% (4/70).
and gynaecology 20.0% (2/5). Positive TOC for urogenital NG was only observed at the GP (overall 16.7%, n = 2).

Regarding extragenital NG, the proportion of TOC performed was 17.9% (7/39) for anorectal NG and 17.1% (6/35) for oropharyngeal NG. Two positive TOC were observed in relation to anorectal, and one in relation to oropharyngeal locations. These positive extragenital TOCs were all performed more than 2 months after the initial positive test.

**Discussion**

This comprehensive overview of NG test practices within a defined Dutch geographical region shows that most men were tested at the STI clinic and most women were tested at their GP. Interestingly, hardly any extragenital NG tests were performed outside the STI clinic. Most NG positives were detected by GPs or at the STI clinic, while hardly any cases were observed in the hospital setting. Moreover, approximately 10% of the patients testing NG positive at the GP were re-tested for a new
infection (after 3 to 12 months), whereas this proportion was ~50% at the STI clinic for extragenital NG. TOC was performed in less than 20% of cases irrespective of STI care provider and anatomical location.

A strength of this study is that we utilised a comprehensive dataset revealing the NG test practice of all main regular STI care providers serving residents of one geographical region. By using unique anonymised codes, we could follow-up NG positive patients and evaluate the frequency/occurrence of both re-testing and TOC. Moreover, the data included information about the anatomical testing site, enabling the evaluation of both urogenital and extragenital NG testing procedures. Finally, NG re-testing practices across three STI care providers were described in detail, which provided valuable information regarding both timing and the patient populations who were re-tested.

One limitation of our study is that we did not have access to more detailed information regarding the characteristics (e.g. sexual orientation) of the individuals tested, which made it impossible to compare NG test practice between e.g. heterosexual men and MSM. Based on the results of a previous Dutch study, we can infer that ~10% of men with a STI-related GP visit are MSM [16].

In addition, we could not evaluate whether TOC was implemented according to current Dutch TOC guidelines, because of missing information regarding pregnancy status, whether or not symptoms were persistent, and which antibiotics were prescribed to NG positive patients [11, 12].

Finally, the time intervals chosen for re-tests and TOC is somewhat debatable. In this study, we have used internationally accepted intervals for re-testing (3–12 months after a test positive visit) and TOC (2 weeks after treatment) [1, 14].

This study is the first of its kind to provide more precise estimates regarding the relative contribution of STI care providers to NG testing in the Netherlands [9]. The STI clinic had the highest contribution to the number of NG tests performed, which was mainly explained by the fact that almost three out of four NG tests in men were performed at the STI clinic. For women, a more equal distribution was observed between GPs and STI clinic, whereas gynaecologists contributed ~20% of all NG tests in women. The fact that men are less likely than women to visit a GP regarding STI-related symptoms has been addressed previously [17].

As well as testing (and treating) men who present with symptoms indicative of NG, GPs need to be aware of the

Table 2 Evaluation of the effects of STI care provider, age, time and social economic status on the number of Neisseria gonorrhoea positives, irrespective of anatomical location

| Provider           | Men Test positivity 3.2% (167/5183) | Women Test positivity 0.8% (80/10,275) |
|--------------------|-------------------------------------|----------------------------------------|
| GP                 | n = 111                             | n = 76                                 |
| STI clinic         | 131                                 | 91                                     |
| Gynaecologist      | 5                                   | 5                                      |

| Age                | Test positivity per category |
|--------------------|-------------------------------|
| 16–21 years        | 1.6                           |
| 22–24 years        | 1.6                           |
| 25–29 years        | 1.1                           |
| 30–39 years        | 1.7                           |
| 40+ years          | 2.1                           |

| SES                | Test positivity per category |
|--------------------|-------------------------------|
| low                | 1.7                           |
| medium             | 1.5                           |
| high               | 1.5                           |

Adj. OR adjusted odds ratio, CI confidence interval, GP general practitioner, STI sexually transmitted infection, SES social economic status, CT Chlamydia trachomatis
Overall P-values for categorical variables were specified by: * P < 0.05 ** P < 0.01
*Calculated by means of multivariable logistic regression analysis, including provider, age, test year and SES
Range of test years: 2006–2010
The numbers given for the SES categories do not add up to the total number of tests performed, because of missing SES data for a proportion of patients
patients tested were in their twenties [16]. GP and gynaecology patients with low SES were more likely to be tested than those with high SES. This association was not observed at the STI clinic, a finding which has previously been explained by the selection of high-risk groups at these clinics which effectively dilutes any effects of SES [10].

We observed that, overall, one in five urogenital NG positive tests were followed by a re-test. More specifically, 35% of urogenital NG positives were re-tested at the STI clinic, while a lower proportion of positives were re-tested at the GP surgery or by a gynaecologist (0–10%). With regard to extragenital NG testing at the STI clinic, this proportion was higher (40–50% were re-tested). It is known that persons who test NG positive have a higher priori chance of testing NG positive again (~10%) [1]. Although our numbers are small, our data also confirms this. In the Netherlands, STI clinics have already adopted the recommendation to re-test between 4 and 6 months after the initial test positive visit [11]. It may be worthwhile for GPs and gynaecologists to include the recommendation for NG re-testing in their guidelines.

With respect to the patient characteristics of person who were re-tested, we observed that older patients with higher SES were more likely to receive a re-test. Future studies could address this evaluation in more depth, for example by including the sexual orientation of patients, to make firm conclusions regarding patient groups that are mainly re-tested.

TOC was performed in ~10% of cases following a urogenital test positive visit, with GPs and gynaecologists performing the test relatively more often, although numbers for gynaecologists were small. High prescription rates of ciprofloxacin by Dutch GPs could explain the higher proportion of TOC performed by the GPs [20].

In relation to extragenital NG, TOC was performed in 15–20% of cases. Several guidelines, including the European guidelines on the diagnosis and treatment of NG in adults and the ones for Dutch STI clinics, have stated that TOC should always follow an oropharyngeal NG treatment, because oropharyngeal NG is more difficult to eradicate than urogenital and anorectal NG, and is frequently asymptomatic [11, 14]. Until now, no ceftriaxone resistance has been detected in the Netherlands [21]. Because this resistance is most likely to emerge in the groups at highest risk for NG, the implementation of this policy is particularly important for patients presenting at the STI clinic. In this respect, the proportion of TOC performed following oropharyngeal NG at the STI clinic (~17%) was low in our study, and needs to be addressed. The 3 positive extragenital TOCs observed in our study, were all performed at the STI clinic more than 2 months after the initial positive test, thus more likely reflecting re-exposure, rather than being an indication of ceftriaxon resistance.

| Table 3 Overview of patient characteristics based on whether a person was re-tested or not after a positive NG test |
|-------------------------------------------------|
| Re-tested | Yes (N = 59) | No (N = 166) | OR (95% CI) |
| Sex       | n (%)*     | n (%)*      |             |
| Men       | 35 (23.5)  | 114 (76.5)  | 1 (ref)     |
| Women     | 24 (31.6)  | 52 (68.4)   | 1.5 (0.8–2.8) |
| Age       |            |             |             |
| 16–21     | 5 (16.7)   | 25 (83.3)   | 1 (ref)     |
| 22–24     | 2 (5.9)    | 32 (94.1)   | 0.3 (0.1–1.7) |
| 25–29     | 14 (30.4)  | 32 (69.6)   | 2.2 (0.7–6.9) |
| 30–39     | 12 (25.5)  | 35 (74.5)   | 1.7 (0.5–5.5) |
| 40+       | 26 (38.2)  | 42 (61.8)   | 3.1 (1.1–9.1)* |
| SES b     |            |             |             |
| low       | 15 (18.3)  | 67 (81.7)   | 1 (ref)     |
| mid       | 17 (22.7)  | 58 (77.3)   | 1.3 (0.6–2.9) |
| high      | 25 (42.4)  | 34 (57.6)   | 3.3 (1.5–7.0)* |
| CT test result |            |             |             |
| negative  | 51 (27.3)  | 136 (72.7)  | 1 (ref)     |
| positive  | 8 (21.1)   | 30 (78.9)   | 0.7 (0.3–1.7) |

*OR odds ratio, CI confidence interval, SES social economic status, CT Chlamydia trachomatis

* The numbers given of the percentages given is the total number of patients per row

b The numbers given for the SES categories do not add up to the total numbers per category, because of missing SES data for a proportion of patients

sexual preference of their male patients. In this way, testing can be targeted towards their MSM patients, a well-known group at-risk for NG [1]. In addition to urogenital testing, and in light of the widely observed high proportion of single site extragenital NG [3, 11], MSM should also be tested for NG both anorectally and oropharyngeally. Importantly, these extragenital sites have been implicated as drivers for NG antimicrobial resistance [18]. The current STI guidelines (2013) for Dutch GPs recommends that extragenital tests should be performed on indication, and this will hopefully be translated into clinical practice [12].

In this perspective, GPs can also draw attention to the possibility of NG self-testing, for example, by providing information leaflets and posters in their practice, because self-collected extragenital NG swabs have been found to be a feasible, valid and acceptable alternative for MSM and women [19].

Most NG tests were performed among patients aged 25–29, irrespective of sex and provider, whereas patients aged 40+ received comparatively fewer tests. This is in line with previous Dutch data in which STI consultations by GPs were evaluated and the highest proportion of
Moreover, STI care providers need to be aware of the timing of TOC by NAAT, as several of those reported here were performed too early, i.e. within a week of the test positive visit, therefore compromising the result (as this can be still based on detection of non-viable nucleic acids after treatment of the NG infection) [22].

Conclusions

Our study of NG test practice showed that, despite the fact that NG can present at ano-rectal and oropharyngeal sites, often without a concurrent urogenital infection, general practitioners and gynaecologists rarely test for extragenital NG, and, as a result, a substantial amount of treatment opportunities are missed. In addition, re-testing yields relatively high positivity rates and, therefore, STI care practitioners should consider NG re-testing to detect new infections following initial NG diagnosis. Finally, it showed that laboratory data on NG testing are useful in order to evaluate and optimise NG test practice.

Abbreviations

CDC: Centers for Disease Control and Prevention; Cl: Confidence interval; CT: Chlamydia trachomatis; GP: General practitioner; GUM: Genitourinary medicine; HIV: Human immunodeficiency virus; MSM: Men who have sex with men; NAAT: Nucleic acid amplification test; NG: Neisseria gonorrhoeae; OR: Odds ratio; PCR: Polymerase chain reaction; RR: Rate ratio; SDA: Strand displacement amplification; SES: Social economic status; STI: Sexually transmitted infection; TOC: Test-of-cure

Acknowledgements

The authors thank the staff of the STI clinic South Limburg and the Department of Medical Microbiology, Zuyiderland Medical Centre Heerlen for their valuable contribution to this work. Moreover, we want to thank Jane Banfield for critically reviewing and editing the English language in this paper.

Funding

No external funding. Investigator initiated.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

ND and CH designed the study, interpreted results and supervised the study. GvL retrieved the data. CdH, article, analysed and interpreted the data. AvB, JC and FS helped with the interpretation of data. All authors commented on the final manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The medical ethics committee of Maastricht University Medical Centre (MUMC) approved the study (identification number 12-4-042). This includes a waiver for consent to participate, because the dataset of this study does not contain any individual person’s identifiable data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1 Department of Medical Microbiology, Maastricht University Medical Centre, CAPHRI School of Public Health and Primary Care, Maastricht, the Netherlands. 2 Department of Sexual Health, Infectious Diseases and Environmental Health, Public Health Service South Limburg, Geleenbeeklaan 2, 6166 GR Geleen, the Netherlands. 3 Department of General Practice, University of Amsterdam, Amsterdam, the Netherlands. 4 Soa Aids Nederland, Amsterdam, the Netherlands. 5 Department of Family Medicine, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, the Netherlands. 6 Department of Medical Microbiology, Zuyiderland Medical Centre, Heerlen, the Netherlands.

Received: 13 December 2016 Accepted: 20 April 2017

Published online: 20 April 2017

References

1. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR. 2015; 64(RR-03):1–137.
2. Farley TA, Cohen DA, Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med. 2003;36:502–9.
3. Dukers-Muijters NH, Schachtier J, van Liere GA, Wolfs PF, Hoebe CJPA. What is needed to guide testing for ano-rectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion. BMC Infect Dis. 2015;15:933.
4. Detels R, Green AM, Klausner JD, Katzenstein D, Gaydos C, Handsfield H, et al. The incidence and corelates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries. Sex Transm Dis. 2011;38:503–9.
5. UK national gonorrhoeae guidelines: http://www.bashh.org/documents/3920.pdf. Accessed 12 Dec 2016.
6. Low N, Cassell JA, Spencer B, Bender N, Hilmer AM, van Bergen JEAM, et al. Chlamydia control activities in Europe: cross-sectional survey. Eur J Pub Health. 2012;22:556–61.
7. Santella AJ, Pollack A, Harrison C, SawleshwarSK, Brit HC, Hillman RJ. Management rates of sexually transmissible infections by Australian general practitioners, 2000-2012. Sex Health. 2014;11:52–7.
8. Wetten S, Mohammed H, Yung M, Mercer CH, Cassell JA, Hughes G. Diagnosis and treatment of chlamydia and gonorrhoea in general practice in England 2000-2011: a population-based study using data from the UK Clinical Practice Research Datalink. BMU Open. 2015;5:e007776.
9. Van den Broek IV, Verheij RA, van Dijk CE, Koedijk FD, van der Sande MA, van Bergen JEAM. Trends in sexually transmitted infections in the Netherlands, combining surveillance data from general practices and sexually transmitted infection centers. BMC Fam Pract. 2010;11:39.
10. Den Heijer C2, van Liere GAFS, Hoebe CJPA, van Bergen, JEAM, Cals AW, Stals FS, et al. Who tests whom? A comprehensive overview of Chlamydia trachomatis test practices in a Dutch region among different STI care providers for urogenital, ano-rectal and oropharyngeal sites in young people: a cross-sectional study. Sex Transm Infect. 2015;92:211–7.
11. STI test policy for Dutch STI clinics: http://www.rivm.nl/diresource?objectid=94096d6d-ae14-40f9-b88a-60f10883bc4&type=pdf&disposition=inline. Accessed 9 Mar 2017.
12. Veerle EL, van Bergen JE, Dekker JH, Boeke AJ, Burgers JS, Boursma M. Summary of the NHG guideline 'The STD consultation'. Ned Tijdschr Geneeskd. 2014;158:A7277.
13. HJC de Vries, GJJ van Doornum, CJ Bax, Van Bergen JEAM, de Bes J, Van Dam AP, et al. Multidisciplinaire Richtlijn Seksueel Overdraagbare Aandoeningen voor de 2e Lijn, Nederlandse Vereniging voor Dermatologie en Venereologie, 2012. http://www.nvdn.nl/wp-content/uploads/2014/08/Multidisciplinaire-richtlijn-3920.pdf. Accessed 9 Mar 2017.
14. Bignell C, Unemo M, European STI, Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;2:485–92.
15. Krijnou M, Soetsens LC, Koedijk FE, Department of General Practice, University of Amsterdam, Amsterdam, the Netherlands. 26. Van der Sande MA, Wallinga J. Public health measures to control the spread of antimicrobial resistance in Neisseria gonorrhoeae in men who have sex with men. Epidemiol Infect. 2015;143:1575–84.
16. Trienekens SC, van den Broek IV, Donker GA, Van Bergen JEAM, van der Sande MA. Consultations for sexually transmitted infections in the general
practice in the Netherlands: an opportunity to improve STI/HIV testing. BMJ Open. 2013;3:e003687.

17. Woestenberg PJ, van Oeffelen AA, Stirbu-Wagner I, van Benthem BH, van Bergen JEAM, van den Broek IV. Comparison of STI-related consultations among ethnic groups in the Netherlands: an epidemiologic study using electronic records from general practices. BMC Fam Pract. 2015;16:70.

18. Barbee LA. Preparing for an era of untreatable gonorrhea. Curr Opin Infect Dis. 2014;27:282–7.

19. Van der Helm JJ, Hoebe CJP, van Rooijen MS, Brouwers EE, Fennema HS, Thiebrummel HF, et al. High performance and acceptability of self-collected rectal swabs for diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men who have sex with men and women. Sex Transm Dis. 2009;36:493–7.

20. Koedijk FD, van den Broek I, Stirbu-Wagner I, et al. Gonococci change more quickly than prescribing practices; resistance to frequently prescribed antibiotics. Ned Tijdschr Geneeskd. 2013;157:A5642.

21. NethMap-MARAN 2016; Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands in 2014; Nethmap: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands: http://www.wur.nl/upload_mm/0/b/c/433ca2d5-c97f-4aa1-ad34-a4Sd522df95_92416_008804_NethmapMaran2016+TG2.pdf.

22. Wind CM, van der Loeff MF S, Unemo M, Schuurman R, van Dam AP, de Vries HJ. Test of Cure for Anogenital Gonorrhoea Using Modern RNA-Based and DNA-Based Nucleic Acid Amplification Tests: A Prospective Cohort Study. Clin Infect Dis. 2016;62:1348–55.